Growth in this market is mainly driven by the rising demand for donated blood, the growing number of blood donations across the world, and the rising prevalence of infectious diseases.
The global Blood screening market is projected to reach USD 3.8 billion by 2026 from
USD 2.5 billion in 2021, at a CAGR of 8.4% during the forecast period.
Request Sample Pages:- https://www.marketsandmarkets.com/requestsampleNew.asp?id=267747042
The key players in this
market are Grifols (Spain), F. Hoffmann-La Roche Ltd. (Switzerland), Abbott
Laboratories, Inc. (US), bioMérieux (France), Bio-Rad Laboratories, Inc.
(US), Becton, Dickinson and Company (US), Beckman Coulter, Inc. (Danaher) (US),
DiaSorin (Italy), Siemens Healthineers (Germany), Thermo Fisher Scientific,
Inc. (US), Ortho Clinical Diagnostics Inc. (US), GE Healthcare (US), Merck KGaA
(Germany), PerkinElmer (US), Bio-Techne Corporation (US), GFE (Germany),
Trinity Biotech (Ireland), Mindray (China), Maccura Biotechnology Co., Ltd.
(China), Immucor, Inc. (US), Cellabs (Australia), Abnova Corporation (Taiwan),
Enzo Biochem, Inc. (US), and Cepheid (US).
In 2020, F. Hoffmann-La
Roche Ltd. held the leading position in the blood screening market. The
company’s leading position in this market can be attributed to its strong
global sales and distribution network, enabling it to market its products in
various countries effectively. In addition, F. Hoffmann-La Roche Ltd. invests a
significant amount of its revenue on R&D. This enables the company to
develop and launch new products in the market. In March 2021, the company
launched its Cobas 6800/8800 systems. Additionally, in March 2021, the company
launched its Cobas SARS-CoV-2 Variant Set 1 Test. These tests were developed
for the accurate detection and differentiation of SARS-CoV-2 mutations.
In 2020, Grifols accounted
for the second-largest share of the blood screening market. The company has
maintained a leading position in the market through its strong distribution
networks across North America, Europe, the Asia Pacific, Latin America, and the
Middle East and Africa. The company adopts inorganic growth strategies to
increase its dominance in this market. For instance, in September 2021, the
company acquired Biotest (Germany). This acquisition strengthened Grifols’s
position as a leading innovator in procedural plasma medicines across the
world. Such developments will enable Grifols to add innovative technologies and
products to its portfolio, which, in turn, will strengthen its presence in the
blood screening market.
Download PDF Brochure :- https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=267747042
No comments:
Post a Comment